About Akari Therapeutics, Plc
https://www.akaritx.comAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
CEO
Abizer Gaslightwala
Compensation Summary
(Year 2015)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-08-21 | Reverse | 1:20 |
| 2023-08-17 | Reverse | 1:20 |
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
CRESSET ASSET MANAGEMENT, LLC
Shares:822.47K
Value:$220.01K
VHCP MANAGEMENT, LLC
Shares:158.35K
Value:$42.36K
PALO ALTO INVESTORS LP
Shares:146.02K
Value:$39.06K
Summary
Showing Top 3 of 20
About Akari Therapeutics, Plc
https://www.akaritx.comAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.21M ▼ | $-6.36M ▼ | 0% | $-19.48K ▼ | $-7.32M ▼ |
| Q2-2025 | $0 | $3.12M ▼ | $-1.9M ▲ | 0% | $-120.4 ▲ | $-1.84M ▲ |
| Q1-2025 | $0 | $3.52M ▼ | $-3.71M ▲ | 0% | $-280 ▼ | $-3.65M ▼ |
| Q4-2024 | $0 | $4.29M ▲ | $-3.77M ▼ | 0% | $-40 ▲ | $-3.65M ▼ |
| Q3-2024 | $0 | $2.93M | $-2.9M | 0% | $-240 | $-2.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.48M ▼ | $45.38M ▼ | $22.69M ▼ | $22.69M ▼ |
| Q2-2025 | $2.71M ▲ | $50.91M ▼ | $25.31M ▼ | $25.61M ▲ |
| Q1-2025 | $2.58M ▼ | $50.96M ▲ | $29.21M ▲ | $21.75M ▼ |
| Q4-2024 | $2.6M ▲ | $50.56M ▲ | $28.33M ▲ | $22.23M ▲ |
| Q3-2024 | $2.25M | $2.73M | $9.43M | $-6.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.36M ▼ | $-2.1M ▲ | $0 | $1.88M ▼ | $-227K ▼ | $-2.1M ▲ |
| Q2-2025 | $-1.9M ▲ | $-3.26M ▼ | $0 | $3.38M ▲ | $129K ▲ | $-3.26M ▼ |
| Q1-2025 | $-3.71M ▲ | $-2.15M ▼ | $0 ▼ | $2.13M ▼ | $-17K ▼ | $-2.15M ▼ |
| Q4-2024 | $-3.77M ▼ | $-2.12M ▼ | $382K ▲ | $2.15M ▲ | $413K ▲ | $-2.12M ▼ |
| Q3-2024 | $-2.9M | $-1.49M | $0 | $-443K | $-1.93M | $-1.49M |
CEO
Abizer Gaslightwala
Compensation Summary
(Year 2015)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-08-21 | Reverse | 1:20 |
| 2023-08-17 | Reverse | 1:20 |
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
CRESSET ASSET MANAGEMENT, LLC
Shares:822.47K
Value:$220.01K
VHCP MANAGEMENT, LLC
Shares:158.35K
Value:$42.36K
PALO ALTO INVESTORS LP
Shares:146.02K
Value:$39.06K
Summary
Showing Top 3 of 20